Author:
Dangoor David,Rubinraut Sara,Fridkin Mati,Gozes Illana
Reference12 articles.
1. Said, S.I., and Mutt, V. A peptide fraction from lung tissue with prolonged peripheral vasodilator activity Scand. J. Clin. Lab. Invest., 1969; 107: 51–56.
2. Gozes, I., and Furman, S. VIP and drug design. Curr. Pharm. Des., 2003; 9(6): 483–494.
3. Said, S.I. Vasoactive intestinal polypeptide biologic role in health and disease. Trends Endocrin. Metab., 1991; 2(3): 107–112.
4. Gozes, I., et al. Pharmaceutical VIP: Prospects and problems. Curr. Med. Chem., 1999; 6(11): 1019–1034.
5. Gozes, I., et al. Stearyl-norleucine-vasoactive intestinal peptide (VIP): A novel VIP analog for noninvasive impotence treatment. Endocrinology, 2004; 134(5): 2121–2125.